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Article 1

Organ Transplantation:
The Ethics of Consequences
by
Elora J. Weringer, Ph.D.
The author has been Senior Research Investigator for Pfizer, Inc. There,
she conducted drug discovery research programs in immunology of
transplantation and autoimmune diseases.

Organ allograft transplantation, as a life-saving procedure for those in endstage irreversible organ failure, has benefited and progressed because of
the innovations in clinical and pharmacological research. Advancing the
early studies in transplantation Dr. Joseph Murray and colleagues were
among the first to use pharmacological agents in transplant patients. I
Initially, the agents used to enhance graft acceptance were either cytotoxic
and suppressed all dividing cells in the body or cytostatic, such as the
steroids, which attenuated the immune cells. 2 These drugs, however, were
non-specific, had unpredictable efficacy, and usually grave side effects. As
knowledge and understanding of the immune system unfolded, so did new
concepts for designing better methods of preventing organ allograft
rejection. Early on, attention centered on the theory of graft "foreignness",
but in the era of molecular biology, it has expanded to include the
intricacies of the intracellular environment and the events, which comprise
the recognition, activation and cellular proliferation of the immune
response. This science has unmasked new strategies for the identification
of targets for immunopharmacological intervention, so that each phase in
the intracellular signaling system is available for modification or inhibition
to alleviate the aggressive response that destroys the transplanted organ.
Now more specific agents, which are directed to a distinct component
of the immune response, are used to inhibit the initiation phase. In 1984,
the discovery and use Cyclosporin-A (CsA), a powerful new
immunosuppressive drug that Jowers significantly the chances of rejecting
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the new organ, truly revolutionized the field of organ transplantation and is
to this day the mainstay of clinical immunosuppression. CsA is selective
for T cells and devoid of bone marrow cytotoxicity and is also a valued
probe for medical and pharmacological research.3 It is not, however,
without unwanted side effects, which often increase with duration of
therapy. For an allograft to function indefinitely immunosuppressive
therapy must be taken continuously.
Most recently, research in immunology has expanded to investigate
the totality of the immune response, including cellular communication and
the signals that govern it. This approach provides the precision and
discrimination to target the cells immediately involved in the immune
response, and not the immune cells responsible for prevention of disease.
The untold advantage to this method is the development of a stable
tolerance where the immune system no longer detects the graft as foreign
and the graft survives without further immunosuppression. 4 The great
scientific and clinical investigations and advances in organ transplantation
have evoked some novel ethical questions and consequences.
Unquestionably, as organ transplantation has become more successful and
available, one of the major, if not the most significant, ethical questions to
be resolved is the gap between the number of recipients in need of vital
organs and the availabiJity of life-saving donor organs for transplantation.
Organ procurement and allocation presents some of the major moral
problems in medicine: the role of the physician and surgeon, patient
autonomy, respect for the dying and the deceased, and the equitable
distribution of scarce resources. First, since the majority (> 85%) of
transplantable organs, primarily kidneys, are from cadaver donors, the
definition of death has been a problematic issue. Ontologically, death is the
loss of personhood, but medically quantitative criteria are required. In
1968, the concept of brain death was formulated at Harvard Medical
School in direct response to the transplant teams, and replaced the former
criteria of cardiopulmonary cessation. 5 In 1981, the Committee on Morals
and Ethics of the Transplantation Society articulated the objective
judgment of death as the irreversible cessation of all brain function, so that
the decision was made independent of the transplant team and the need for
organs. 6 The concern was to ensure that organ donation was not connected
with the definition of death; this is a potential and dangerous sortie into the
discussion of the worth and existence of a life.
Secondly, what comprises informed consent for organ donation? In
the United States, informed consent requires explicit consent from the
donor before death by written advance directives, called "opting-in", or by
proxy consent from the next-of-kin. Individuals may also "opt-out" of
donation through a written directive of refusal. In other countries societal
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needs are placed above individual autonomy and altruism. The 1976
Presumed Consent Law in France argues that the needs of society outweigh
those of the individual to control bodily remains after death.? Austria has
adopted a policy whereby the state assigns dominion over bodies to
physicians for important social purposes such as research and organ
transplantation.
To increase organ donation in the United States, the 1986 Omnibus
Reconciliation Act mandated that all federally funded hospitals make a
required request to ensure that every potential donor be notified of the
transplant option and asked to make a donation and that organ procurement
agencies be notified of potential donors.8 Nonetheless, the moral means of
organ donation is traditionally by voluntary consent based on altruism.
Approximately fifteen per cent of kidney transplants are from livingrelated donors, which raises some serious social and ethical questions
regarding this procedure as often both the donor and recipient are minors.
Elective nephrectomy to save the life of another human being is a serious
issue to be weighed with great responsibility and deserving of deep moral
reflection by the patients (if they are of age), the family, the physician, and
the surgeon. Dr. Murray has written that the volunteer donor must, without
coercion, freely consent to the act of donation as a gift, which in essence is
the purest form of charity.9 Further, the donor must not be deprived of the
opportunity to save a loved one. According to Clinical Bioethicist, Dr.
Pellegrino, the doctor, using the virtue of prudence, seeks to preserve
human life by means based on unyielding concern for the welfare of the
individual patient. 10
These and other attempts to increase organ donation have been
implemented to combat the current climate of commercialization and the
covert buying and selling of organs. The hazards of commodification of
organs are imminent. Proposals for a marketing and business approach to
organ collection have been put forward by health policy analyst, Jeffrey
Prottas, who argues that organ donation and procurement is more than a
moral enterprise. I I It should be regarded as a not-for-profit industry that
engages and encourages altruism. Others, moving beyond the idea of
donation as gift, have proposed the adoption of a system of financial
incentives or regulated compensation to organ donors or their next of kin as
a mechanism to increase the supply of organs. 12 Their intent is to foster
greater efficiency and coordination in the allocation process; and even if it
is morally marginal, it is preferable to the acceptance of suffering and death
of those who cannot get transplants. 13 In shifting from a gift to a market
model, the conviction that economic and social ethics should be guided by
the maximization of rational, self-interested free choices is without doubt
materialistic individualism. Will human organs become legitimated market
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commodities rather than altruistic gifts of life? The outcome will depend
on the moral standing of society more than the shortage of organs. The sale
of organs was condemned by the World Health Organization in 1947, the
World Medical Association in 1985, the International Transplant Society in
1985, and was prohibited by the 1984 National Organ and Transplant Act. 14
This recurrent concept is morally repugnant and devalues all altruism
and solidarity within the community. We, as humans, are not possessors,
but stewards of our bodies as gifts from God. The community as the elected
steward of the gifts of donated organs has the responsibility to implement
policies for the allocation of scarce and life-saving resources in an
equitable and just manner and to preserve what David Lamb has termed the
symbolism of transplantation as relationship. IS For within the context of
organ transplantation are all the deeper questions concerning what it means
to be a human being, to have obligations towards others and to belong to
the human family.
The allocation of organs requires political and ethical imperatives for
the efficient management of medical resources through an equitable and
fair system of distribution. Such policy decisions may be based on
principles of social utility, which measures the patient's capacity to benefit
society - judgments that are prone to subjectivity and prejudice; on
principles of distributive justice, which seek to maximize the fairness of the
claims of all to basic goods - policies that may disadvantage the poor and
the marginalized on society; or on egalitarian principles which stress the
equality of worth of all persons as human beings.
Initially, the ownership of donated organs in most organ allocation
policies was under the dispositional authority of the transplant surgeons. In
1986, the Task Force for Organ Transplantation stipulated that donated
organs belonged to the community with the transplant professionals serving
as the trustees or stewards. 16 This rule mandated public accountability and
participation in setting the criteria for organ allocation. Currently, organ
allocation is managed by UNOS (United Network for Organ Sharing), a
federally funded and publicly accountable nationwide organ procurement
and transplant network, which has placed organ allocation in the public
domain. I?
UNOS attempted to make the system equitable by setting criteria and
creating a formula for organ allocation to judge which patient would
benefit most medically from receiving an organ. Specific technical points
such as tissue matching and immunosuppressive therapies, time on the
waiting list, and medical urgency influence judgments concerning
allocation to outside the community or between two patients within the
community. Medical utility for maximum welfare of patients in end-stage
organ failure considers factors that influence both graft and patient survival
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and potential need. When an organ becomes available the most suitable
recipient on the waiting list is identified by a computer match between the
transplant center and UNOS. However, the "right" distribution policy is
still a function of the best clinical judgment. Recently, two novel
technologies have been investigated as alternative sources for organs and
tissues: xenotransplantation and stem cell research.
As a result of the organ donor shortage, which was declared a public
health crisis in 1991, there has emerged new interest in the idea of crossspecies transplantation or xenotransplantation. Xenotransplantation is
appealing because the organs are available, they are biological, in that there
is adequate tissue to support organ physiology, and they are totally
implantable in contrast to artificial devices. 18 Additionally, they can serve
as life-saving biological bridges until a human organ becomes available
and the surgical techniques to implant them are similar to that for human
organs.
With efficacious therapies to inhibit organ and tissue transplant
rejection and unique methods to genetically alter donor animals for
improved compatibility with the host, xenotransplantation is an area of
intense research and debate. Despite the early promising studies, these very
advantages underscore and contribute to the major biological and ethical
hurdles of xenotransplantation. The National Institutes of Health and
Nuffield Foundation for Bioethics in the United Kingdom have held
conferences to define and weigh the major scientific and ethical issues of
xenotransplantation.19 Foremost is the critical issue of cross-species
infectivity and pathogenicity, which questions the balance between
individual patient need and possible danger to society. The potential spread
of endogenous animal pathogens to human xenotransplantation recipients
and possibly to the public is augmented by recipient immunosuppression.
Such long-term therapies weaken the host defenses to infection and
potentially may favor the activation of animal pathogens. Since it is not yet
feasible or possible to raise donor animals that are "clean" and to ensure
against infectious agents carried within donor animal organs, the genetic
manipulation of the donor animals may provide an opportunity for animal
pathogens to adapt to the human host. 20
The Food and Drug Administration (FDA), in an effort to put the
public health first and allow science to catch up with these possible risks,
issued a moratorium on xenotransplant clinical trials. Human trials would
only take place if the risks were deemed low and acceptable. However, the
moratorium was relaxed in favor of "cautious" continuation of the trials
under strict supervision.21
Is this decision tantamount to exposing the public to potentially
serious risks that may have long-term consequences without their consent
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or awareness? This question was posed by Dr. Fritz Bach, from Harvard,
who has directed research in xenotransplantation. He has called for an
additional Hippocratic ethic: to do no harm to the community. He believes
that xenotransplantation requires a wide and informed public debate on
whether this unquantifiable risk to the public is justified by the benefit to
the few or if any trials should be allowed to proceed at present. 23
Other ethical problems raised by the Nuffield Bioethics Commissions
were:
1. Is the imposition of harm (maleficence) on non-humans to benefit
humans ethical? Is xenotransplantation an acceptable means for achieving
this end (helping humans)?
2. What of the cost borne by other patients if the allocation of
resources is redirected away from areas of research and medical care to
new and experimental therapies like xenotransplantation? Is the ensuing
benefit to all an equitable and effective use of resources?
3. Does xenotransplantation undermine human altruism and the
"gift" metaphor? Both Hans Jonas and John Lynch, S.J., view this gift as
one of fraternal love - to give ourselves to others in ways that transcend
what is ordinarily expected of us. 23, 24
The most recent technology of considerable debate is stem cell
research. Scientists have isolated pluripotent stem cells from human
embryos, which hold tremendous promise for treating human diseases. 25
Yet the retrieval of these stem cells results in the destruction of the viable
embryo. The National Institutes of Health, in an effort to forward this
research, argued for a lifting of the congressional ban on embryo research.
In hearings in Washington, DC, June 28-29, 1999, the National Bioethics
Advisory Commission (NBAC), in support of this research, acknowledged
that the embryo is entitled to some respect, but claimed that any respect
given the embryo must be tempered by the benefits or social good that its
stem cells may have for "others" in alleviating suffering.26 This utilitarian
calculus evokes the most basic ethical and moral questions, which have
been addressed by Dr. PellegrinoY First, do human embryos have any
inherent worth independent of any benefit to others and, secondly, does the
embryo have a moral status that protects it? These are questions that must
be considered separately from any potential therapeutic good or
instrumental value of the stem cells. He calls for scientific "moral
constraint" in stem cell research, in that morally unacceptable experiments
should never be done.
Morally and ethically, all human embryos are equally deserving of
protection and respect as most vulnerable members of the human species.
Though it is praiseworthy to apply the latest scientific advances to human
suffering, this noble end cannot be achieved through less than noble means.
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If the life of the human embryo is valued only for its benefit to others, then
all human life is devalued. Scientists are obliged to pursue and support
morally defensible means to accomplish the same end and seek alternate
sources for procuring human stem cells (i .e., human cord blood and bone
marrow) .
In conclusion, what is the ethical responsibility that must govern the
decisions and actions of patients, physicians and the community with
regard to organ transplantation? Organ donation is based on accepted
societal values. All transplantation policies must advance the moral values
and concerns our society has regarding individual autonomy, importance
of family, and dignity of the body. They must also embrace the social
practices that enhance and strengthen altruism and our sense of
community. Transplantation is not a cure - but a hope - and hope is a
unique bond between the patient and the physician, the family, and the
community.28
As stewards of these organs both the transplant professional and the
community have an important role in setting the criteria for organ
procurement, allocation and distribution. The public trust in the prudential
balance between principles of justice and values in these policies confirms
the public 's willingness to donate organs. This trust implies a moral
commitment and responsibility to acknowledge and consider the
universality of human rights and the common good; the opportunity for
each human person to achieve physical and spiritual goods which are owed
to them because of their human dignity. As defined in the Consistent Ethic
of Life and its founder principles, there is an equal dignity of every human
person and the right to life of each human being; and the derived principle,
that any violation of the rights of an innocent human being is unethicaF9
The moral responsibility of all the members of the community, in
solidarity, is to protect and preserve the sacredness and value of human life
and to ensure that this undeniable moral factor is incorporated into public
policies. If we eliminate from consideration our knowledge of ourselves as
moral agents then we will never discover genuine moral knowledge or the
practice of virtue. Either we bring value to experience or we find none. 3D
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